Skip to main content
TipRanks
Go Ultimate75% OFF

Surgery Partners (SGRY) Q2 2026 Earnings Report

390 Followers

SGRY Q2 2026 EPS Results

Actual EPS
$0.10
Consensus EPS
$0.06
Beat/Miss
Beat by +$0.04
One Year Ago EPS
$0.17

SGRY Q2 2026 Revenue Results

Actual Revenue
$848.90M
Expected Revenue
$830.03M
Beat/Miss
Beat by +$18.87M
YoY Revenue Growth
+2.75%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/10/2026
Time
Before Open
Conference Call
Monday, August 10, 2026
SGRY Upcoming Earnings

Surgery Partners's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

SGRY Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 10, 2026|% Change Since:73.60%|
Earnings Call Sentiment|Positive

The call emphasized healthy organic performance (revenue growth, strong same-facility metrics, physician recruiting, case acuity expansion, sequential expense improvements) and a strategic portfolio optimization (Idaho Falls sale) expected to simplify the business, improve cash conversion and reduce leverage. Headwinds include a modest decline in adjusted EBITDA and margins year-to-date, higher interest expense, a ~350 bps decline in commercial mix, elevated leverage metrics, and muted M&A activity in 2026. On balance, the positives (organic growth, operational improvements, substantial deleveraging transaction and reaffirmed guidance) outweigh the negatives.

Company Guidance

Surgery Partners reaffirmed full-year 2026 guidance of revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million (excluding any impact from the pending Idaho Falls transaction) and said it will update guidance promptly after that sale closes; the Idaho Falls transaction is expected to yield approximately $795 million of gross proceeds and reduce consolidated leverage by roughly 0.3 turns. For context, reported Q2 net revenue was about $849 million (up 2.7% YoY) with adjusted EBITDA of about $125 million and a 14.7% adjusted EBITDA margin, while year-to-date net revenue was about $1.66 billion (up 3.6%) with adjusted EBITDA of about $228 million; excluding Idaho Falls, Q2 revenue would have been roughly $660 million with adjusted EBITDA of roughly $98 million (H1 ex-Idaho Falls: ~$1.29 billion revenue and ~$173 million adjusted EBITDA). At quarter end liquidity and leverage metrics included cash of ~$217 million, revolver borrowings of ~$75 million with ~$618 million available capacity, credit-agreement net debt leverage of ~4.4x (balance-sheet net debt/EBITDA ~5.1x), Q2 operating cash flow of ~$59 million (YTD ~$71 million), and Q2 interest of ~ $90 million.

  • Quarterly Revenue GrowthNet revenue of approximately $849M in Q2 2026, up 2.7% year-over-year; year-to-date net revenue of ~$1.66B, up 3.6% year-over-year.
  • Same-Facility PerformanceSame-facility net revenue increased 5.0% in Q2 (4.8% of which was rate-driven). Year-to-date same-facility revenue rose 4.9% with same-facility cases +0.8% and net revenue per case +4.0%.
  • Strong Case Volume and Acuity GrowthApproximately 168,000 surgical cases performed in Q2 driven by orthopedic (total joints, spine) and vascular procedures, reflecting robust acuity-driven growth.
  • Physician Recruiting Momentum191 new physicians began using facilities in Q2 (330 year-to-date). Initial revenue contribution from the 2026 recruit cohort increased nearly 16% versus last year's cohort.
  • Operational Discipline and Sequential Expense ImprovementSequential improvement in operating expense ratios from Q1 to Q2: salaries & wages 29.8% of revenue (down from 30.5%), supplies 26.7% (27.2% prior quarter), professional fees 12.1% (12.5% prior quarter), other op expenses 6.1% (7.3% prior quarter), G&A 4.3% (4.8% prior quarter).
  • Portfolio Optimization Transaction (Idaho Falls)Signed definitive agreements to sell Idaho Falls market to Intermountain Health for gross proceeds of approximately $795M; expected to reduce consolidated leverage by ~0.3 turns and simplify the company to a core short-stay surgical profile.
  • Pro Forma Ex-Idaho Falls MetricsExcluding Idaho Falls, Q2 revenue would have been ~ $660M and adjusted EBITDA ~ $98M; H1 ex-Idaho Falls revenue ~ $1.29B and adjusted EBITDA ~ $173M — providing a clearer view of go-forward profile.
  • Balance Sheet LiquidityQuarter-end cash of approximately $217M, revolver borrowings ~$75M with available revolver capacity of ~$618M; operating cash flow of ~$59M in Q2 (YTD ~$71M).
  • Reaffirmed Full-Year GuidanceReaffirmed 2026 guidance: revenue $3.35B to $3.45B and adjusted EBITDA of at least $530M (guidance excludes potential Idaho Falls transaction impact until close).
  • Development and M&A PipelineSix de novo facilities under construction and seven in the pipeline; disciplined M&A pipeline remains active though 2026 deal activity is muted versus historical average.

SGRY Earnings History

SGRY earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)0.11-0.12――
Nov 09, 20262026 (Q3)0.110.160.1323.08% (+0.03)
Aug 10, 20262026 (Q2)0.060.100.17-41.18% (-0.07)
May 05, 20262026 (Q1)-0.12-0.030.04-175.00% (-0.07)
Mar 02, 20262025 (Q4)0.300.120.44-72.73% (-0.32)
Nov 10, 20252025 (Q3)0.200.130.19-31.58% (-0.06)
Aug 05, 20252025 (Q2)0.180.170.21-19.05% (-0.04)
May 12, 20252025 (Q1)0.070.040.1-60.00% (-0.06)
Mar 03, 20252024 (Q4)0.380.440.440.00% (+0.00)
Nov 12, 20242024 (Q3)0.250.190.190.00% (+0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed